Ltt Bio-Pharma Co., Ltd.

Musashino University

Ea Pharma Co., Ltd.

Tohru Mizushima

Yasunobu Yamashita

Hiroshi Iwata

Naoki Yamakawa

Ken-ichiro Tanaka

Ken-Ichiro Tanaka

To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts and suppresses lung fibrosis without injuring alvocar epithelial cells. A pharmaceutical composition for treating fibrosis, the pharmaceutical composition comprising a compound of formula (I) or formula (II):

Pharmaceutical composition for treating fibrosis

Provided are a quinuclidine derivative of formula (1) and a medicament comprising the quinuclidine derivative:  wherein Rrepresents a hydrogen atom, a halogen atom, a lower alkyl group, a haloalkyl group, a lower alkoxy group, or a haloalkoxy group; Y represents &#x2014;C(C&#x2550;O)&#x2014;O&#x2014;, or &#x2014;CHO&#x2014;; m represents an integer of 1 to 5; Z represents an oxygen atom or a sulfur atom; l represents a number of 0 or 1; n represents an integer of 0 to 4; Xrepresents an anion; and a substituent of a quinuclidine ring represents a 1,3-bond, or 1,4-bond, provided that when m is 3, l is 1, and n is 0, Rrepresents a halogen atom, a lower alkyl group, a haloalkyl group, a lower alkoxy group, or a haloalkoxy group.

Quinuclidine derivative

Growing community of inventors

Minato-ku, Japan

Tohru Mizushima